September 26, 2017

Mountain View, California

Digital Health

Transforming Drug Development


Translational Science Forum

Co-​organized by:



Digital Health Challenge


Have a passion for creating novel digital solutions to solve drug development’s most difficult problems?

Present at the MedImmune California Translational Science Forum on September 26, 2017.

Five finalists will have a chance to win the grand prize by presenting to a panel of prominent industry funding experts and executives:


  • Julia Belaya, Director of Corporate Partnerships, Healthcare Innovation, Plug and Play

  • Yan Cao, Program Director, Diagnostics & Digital Health Catalyst, UCSF Innovation Ventures

  • Alice Jacobs, Advisor, Third Rock Ventures

  • Jane Osbourn, Vice President, R&D, MedImmune

  • John Trainer, Vice President, Strategic Partnering & Business Development, MedImmune

  • Samuel Wu, Managing Partner, Acuris Partners

  • Please click here for more information on our judges.



Applications are no longer accepted. Finalists will be announced Friday, September 15th.



Choose from a list of 5 topics and

submit your best solution!
















Technical Feasibility


Leadership Team





Grand Prize winner will receive $20,000 and mentoring opportunities from MedImmune


All finalists will receive mentoring opportunities from MedImmune


Deadline for entries is 9/8/17– Finalists will be announced by 9/15/17



Mhealth solution for early detection of asthma symptoms and disease monitoring


Data mining to maximize patient recruitment (e.g. patient inclusion and exclusion criteria)


Digital solution to improve site and patient trial experience, e.g. communication, just-​in-​time reminders, trial progress reporting, virtual visits


Integrated analytical platform for collecting and analyzing physiological parameters, symptoms and digital biomarkers (e.g. glucose, weight, activity, sleep etc.)


Digital solutions to simplify and accelerate end to end clinical trial execution, including overall trial management, real time data access and review and drug adverse event data reporting


© MedImmune 2017